Why the study?
What are the current indications and expected beneficial effects of intravenous nitroglycerin in acute myocardial infarction and perioperative CABG hypertension?
What are the current indications and expected beneficial effects of intravenous nitroglycerin in acute myocardial infarction and perioperative CABG hypertension?
Intravenous nitroglycerin is a useful therapeutic option for managing acute myocardial infarction and acute hypertension in the perioperative CABG setting.
May support IV nitroglycerin in acute MI and perioperative CABG hypertension; leaves open need for prospective trials in current practice.
Sublingual nitroglycerin has been the time-honored therapy for angina pectoris for nearly a century. Sustained-action oral forms and cutaneous ointment have been used for perhaps ten years for prophylactic treatment of angina and even more recently have been recommended for use in congestive failure. For the past six years investigators at Johns Hopkins Hospital have been administering intravenous nitroglycerin to patients with acute myocardial infarction with and without left ventricular failure. More recently, we have employed intravenous nitroglycerin to manage acute hypertension developing in patients before and after coronary artery bypass graft surgery. I would like to review with you the current indications for intravenous nitroglycerin and the beneficial effects that would be expected in each clinical situation. I will draw on our own clinical experience obtained in nearly 200 patients and, when necessary, on the recent medical literature.
No takes yet. Share an insight, caveat, or question.
John T. Flaherty (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: